Form 8-K - Current report:
SEC Accession No. 0001558370-25-002097
Filing Date
2025-03-04
Accepted
2025-03-04 07:05:10
Documents
15
Period of Report
2025-03-04
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K capr-20250304x8k.htm   iXBRL 8-K 38882
2 EX-99.1 capr-20250304xex99d1.htm EX-99.1 18062
3 GRAPHIC capr-20250304xex99d1001.jpg GRAPHIC 5626
  Complete submission text file 0001558370-25-002097.txt   188150

Data Files

Seq Description Document Type Size
4 EX-101.SCH capr-20250304.xsd EX-101.SCH 3253
5 EX-101.LAB capr-20250304_lab.xml EX-101.LAB 15264
6 EX-101.PRE capr-20250304_pre.xml EX-101.PRE 9652
17 EXTRACTED XBRL INSTANCE DOCUMENT capr-20250304x8k_htm.xml XML 4636
Mailing Address 8840 WILSHIRE BLVD 2ND FLOOR BEVERLY HILLS CA 90211
Business Address 8840 WILSHIRE BLVD 2ND FLOOR BEVERLY HILLS CA 90211 (310) 358-3200
CAPRICOR THERAPEUTICS, INC. (Filer) CIK: 0001133869 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34058 | Film No.: 25701500
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)